Trademark: 79250207
Word
VETTER-JECT
Status
Registered
Status Code
700
Status Date
Tuesday, July 19, 2022
Serial Number
79250207
Registration Number
6791709
Registration Date
Tuesday, July 19, 2022
Mark Type
4000
Filing Date
Monday, September 24, 2018
Published for Opposition
Tuesday, May 3, 2022

Trademark Owner History

Classifications
39 Bottling services, namely, bottling of liquid and solid substances, in particular of pharmaceuticals, medicines and solutions
5 Pharmaceutical preparations and medicines for the treatment of infections, cancer, depression, heart disease, vascular disease, intestinal disorder, lung and bronchial disfunction, liver disfunction, inflammation and inflammatory diseases, oral and laryngeal disease, optical and cranial disorders, arthritis, migraine, mucopolysaccharidosis, haemophilia, multiple sclerosis, osteoporosis, neuronal disorders, diabetes, erectile disfunction, infertility, crohn's disease, hereditary angioedema, thrombosis, encephalitis, diseases of the thyroid or parathyroid glands, metabolic diseases, muscular atrophy, disturbance of growth and anemia; pharmaceutical solutions for oral administration in the nature of sterile aseptic solutions, namely in the form of tablets, pills, capsules, drops, medical juice and medical syrup, all for the treatment of infections, cancer, depression, heart disease, vascular disease, intestinal disorder, lung and bronchial disfunction, liver disfunction, inflammation and inflammatory diseases, oral and laryngeal disease, optical and cranial disorders, arthritis, migraine, mucopolysaccharidosis, haemophilia, multiple sclerosis, osteoporosis, neuronal disorders, diabetes, erectile disfunction, infertility, crohn's disease, hereditary angioedema, thrombosis, encephalitis, diseases of the thyroid or parathyroid glands, metabolic diseases, muscular atrophy, disturbance of growth and anemia; injectable pharmaceuticals in the nature of antibody solutions, biologicals, peptides, polypeptides, proteins, enzymes, nucleic acids, coagulation factors, interferons, phosphonates and bisphosphonates, growth factors, hormones, hormoneantagonists, insulin, heparins, low molecular heparins and sulfur hexafluoride, all for the treatment of infections, cancer, depression, heart disease, vascular disease, intestinal disorder, lung and bronchial disfunction, liver disfunction, inflammation and inflammatory diseases, oral and laryngeal disease, optical and cranial disorders, arthritis, migraine, mucopolysaccharidosis, haemophilia, multiple sclerosis, osteoporosis, neuronal disorders, diabetes, erectile disfunction, infertility, crohn's disease, hereditary angioedema, thrombosis, encephalitis, diseases of the thyroid or parathyroid glands, metabolic diseases, muscular atrophy, disturbance of growth and anemia; eyedrops, contact lens solutions; medicated compresses; medical plasters, materials for dressings in the nature of bandages, wadding and gauze; filled medical injection devices, in particular syringes and instruments for injections, injectors, auto-injectors and single-chamber and dual-chamber disposable syringes, all sold filled with pharmaceutical preparations for the treatment of infections, cancer, depression, heart disease, vascular disease, intestinal disorder, lung and bronchial disfunction, liver disfunction inflammation and inflammatory diseases, oral and laryngeal disease, optical and cranial disorders, arthritis, migraine, mucopolysaccharidosis, haemophilia, multiple sclerosis, osteoporosis, neuronal disorders, diabetes, erectile disfunction, infertility, crohn's disease, hereditary angioedema, thrombosis, encephalitis, diseases of the thyroid or parathyroid glands, metabolic diseases, muscular atrophy, disturbance of growth and anemia
10 Empty medical injection devices, in particular syringes and instruments for injections, injectors, auto-injectors and single-chamber and dual-chamber disposable syringes, all sold empty; medicine containers for administering medicines, of glass and/or plastic in the nature of medical syringes, injectors, auto-injectors, disposable syringes and disposable cannulae; syringe holders being containers specially adapted for holding medical syringes; medical syringes, disposable syringes, and disposable cannulae sold either individually or in combination, all for medical purposes
42 Development of syringes and instruments for injections, injectors and packaging for the aforesaid goods; laboratory tests in the nature of scientific testing in the fields of chemical, physics and process engineering; product development and conducting of scientific tests in the fields of pharmacological and microbiological processes
VETTER-INJECT

Trademark Events
Nov 14, 2022
Final Decision Transaction Processed By Ib
Oct 22, 2022
Final Disposition Notice Sent To Ib
Oct 22, 2022
Final Disposition Processed
Oct 19, 2022
Final Disposition Notice Created, To Be Sent To Ib
Jul 19, 2022
Notice Of Registration Confirmation Emailed
Jul 19, 2022
Registered-Principal Register
May 9, 2022
Notification Processed By Ib
May 3, 2022
Official Gazette Publication Confirmation E-Mailed
May 3, 2022
Published For Opposition
Apr 13, 2022
Notification Of Possible Opposition Sent To Ib
Apr 13, 2022
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Apr 13, 2022
Notification Of Notice Of Publication E-Mailed
Mar 27, 2022
Approved For Pub - Principal Register
Mar 26, 2022
Teas/Email Correspondence Entered
Mar 25, 2022
Correspondence Received In Law Office
Mar 25, 2022
Teas Request For Reconsideration Received
Sep 27, 2021
Notification Of Subsequent Final Emailed
Sep 27, 2021
Continuation Of Final Refusal E-Mailed
Sep 27, 2021
Action Continuing A Final - Completed
Jul 28, 2021
Suspension Checked ¿ To Attorney For Action
May 16, 2021
Notification Of Possible Opposition - Processed By Ib
Apr 28, 2021
Notification Of Possible Opposition Sent To Ib
Apr 28, 2021
Notification Of Possible Opposition Created, To Be Sent To Ib
Oct 2, 2020
Report Completed Suspension Check Case Still Suspended
Mar 12, 2020
Notification Of Letter Of Suspension E-Mailed
Mar 12, 2020
Letter Of Suspension E-Mailed
Mar 12, 2020
Suspension Letter Written
Mar 10, 2020
Teas/Email Correspondence Entered
Mar 10, 2020
Correspondence Received In Law Office
Mar 10, 2020
Assigned To Lie
Mar 4, 2020
Teas Request For Reconsideration Received
Mar 5, 2020
Notification Of Letter Of Suspension E-Mailed
Mar 5, 2020
Letter Of Suspension E-Mailed
Mar 5, 2020
Suspension Letter Written
Dec 6, 2019
Correction From The Ib Examined, No Action Is Needed
Nov 29, 2019
Correction Transaction Received From Ib
Sep 5, 2019
Notification Of Final Refusal Emailed
Sep 5, 2019
Final Refusal E-Mailed
Sep 5, 2019
Final Refusal Written
Aug 13, 2019
Teas/Email Correspondence Entered
Aug 13, 2019
Correspondence Received In Law Office
Aug 13, 2019
Teas Response To Office Action Received
Mar 2, 2019
Refusal Processed By Ib
Feb 13, 2019
Non-Final Action Mailed - Refusal Sent To Ib
Feb 12, 2019
Refusal Processed By Mpu
Feb 5, 2019
Non-Final Action (Ib Refusal) Prepared For Review
Feb 4, 2019
Non-Final Action Written
Feb 1, 2019
Application Filing Receipt Mailed
Jan 28, 2019
Assigned To Examiner
Jan 28, 2019
New Application Office Supplied Data Entered In Tram
Jan 24, 2019
Sn Assigned For Sect 66a Appl From Ib

Trademark Alertz updated from USPTO on 2030-01-24